These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
490 related items for PubMed ID: 392179
1. [Vitamin D metabolism in kidney insufficiency: disorders of an endocrine regulatory zone]. Ritz E, Kreusser W, Boland R, Bommer J. Klin Wochenschr; 1979 Oct 01; 57(19):1053-9. PubMed ID: 392179 [Abstract] [Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L. Dan Med Bull; 2008 Nov 01; 55(4):186-210. PubMed ID: 19232159 [Abstract] [Full Text] [Related]
3. Vitamin D and type II sodium-dependent phosphate cotransporters. Kido S, Kaneko I, Tatsumi S, Segawa H, Miyamoto K. Contrib Nephrol; 2013 Nov 01; 180():86-97. PubMed ID: 23652552 [Abstract] [Full Text] [Related]
4. Vitamin D metabolites and bone mineralization in man. Bordier P, Rasmussen H, Marie P, Miravet L, Gueris J, Ryckwaert A. J Clin Endocrinol Metab; 1978 Feb 01; 46(2):284-94. PubMed ID: 750606 [Abstract] [Full Text] [Related]
7. Recent advances in pediatric metabolic bone disease: the consequences of altered phosphate homeostasis in renal insufficiency and hypophosphatemic vitamin D-resistant rickets. Pettifor JM. Bone Miner; 1990 Jun 01; 9(3):199-214. PubMed ID: 2163713 [Abstract] [Full Text] [Related]
11. Metabolism of vitamin D: current status. DeLuca HF. Am J Clin Nutr; 1976 Nov 01; 29(11):1258-70. PubMed ID: 187053 [Abstract] [Full Text] [Related]
12. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. J Nephrol; 2006 Nov 01; 19(5):566-77. PubMed ID: 17136683 [Abstract] [Full Text] [Related]
14. Insulin secretion in uremia: effect of parathyroid hormone and vitamin D metabolites. Mak RH. Kidney Int Suppl; 1989 Nov 01; 27():S227-30. PubMed ID: 2699996 [Abstract] [Full Text] [Related]
16. Vitamin D: recent advances. DeLuca HF, Schnoes HK. Annu Rev Biochem; 1983 Nov 01; 52():411-39. PubMed ID: 6311080 [Abstract] [Full Text] [Related]
17. Abnormal expression and regulation of vitamin D receptor in experimental uremia. Szabó A, Ritz E, Schmidt-Gayk H, Reichel H. Nephron; 1996 Nov 01; 73(4):619-28. PubMed ID: 8856261 [Abstract] [Full Text] [Related]
18. Calcium and phosphorus metabolism in chronic uremia. Fiaschi E, Mioni G, Maschio G, D'Angelo A, Ossi E. Nephron; 1975 Nov 01; 14(2):163-80. PubMed ID: 1093055 [Abstract] [Full Text] [Related]
19. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ. J Clin Invest; 1984 Dec 01; 74(6):2136-43. PubMed ID: 6549016 [Abstract] [Full Text] [Related]
20. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Sela-Brown A, Russell J, Koszewski NJ, Michalak M, Naveh-Many T, Silver J. Mol Endocrinol; 1998 Aug 01; 12(8):1193-200. PubMed ID: 9717845 [Abstract] [Full Text] [Related] Page: [Next] [New Search]